Current Location:Home > Team >
Liang Cheng

Liang Cheng, Ph.D., is currently an Associate Professor of Soochow University. He obtained his Ph.D. degree in Pharmaceutical Sciences in December 2010 from Shanghai Jiaotong University under the supervision of Prof. Dr. Shengrong Guo. After that, he joined College of Pharmaceutical Sciences at Soochow University as a staff from 2010 to now. From 2012, he joined Soochow University Biomedical Polymers Lab as a post-doctoral fellow. He has published over 20 peer-reviewed articles. His current research focus is to design “smart” biodegradable nano-scale systems for hepatocellular carcinoma targeted therapy.

Representative Papers

1. Hu W, Qiu L, Cheng L, Hu Q, Liu Y, Hu Z, et al. Redox and pH dual responsive poly(amidoamine) dendrimer-poly(ethylene glycol) conjugates for intracellular delivery of doxorubicin. Acta Biomaterialia 2016;36:241-253.

2. Qiu L, Hu Q, Cheng L, Li L, Tian C, Chen W, et al. cRGDyK modified pH responsive nanoparticles for specific intracellular delivery of doxorubicin. Acta Biomaterialia 2016;30:285-298.

3. Zhong Y, Goltsche K, Cheng L, Xie F, Meng F, Deng C, et al. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo. Biomaterials 2016;84:250-261.

4. Cheng L, Hu Q, Cheng L, Hu W, Xu M, Zhu Y, et al. Construction and evaluation of PAMAM–DOX conjugates withsuperior tumor recognition and intracellular acid-triggered drug release properties. Colloids and Surface B: Biointerfaces 2015;136:37-45.

5. Hu W, Cheng L, Cheng L, Zheng M, Lei Q, Hu Z, et al. Redox and pH-responsive Poly (amidoamine) dendrimer-poly (ethylene glycol) conjugates with disulfide linkages for efficient intracellular drug release. Colloids and Surface B: Biointerfaces 2014;123:254-263.

6. Zhu Y, Cheng L (co-first author), Cheng L, Huang F, Hu Q, Li L, et al. Folate and TAT Peptide Co-Modified Liposomes Exhibit Receptor-Dependent Highly Efficient Intracellular Transport of Payload In Vitro and In Vivo. Pharmaceutical Research 2014;31:3289-3303.

7. Cheng L, Huang F, Cheng L, Zhu Y, Hu Q, Li L, et al. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation. International Journal of Nanomedicine. 2014;9:921-935.

8. Wei R, Cheng L, Zheng M, Cheng R, Meng F, Deng C, et al. Reduction-Responsive Disassemblable Core-Cross-Linked Micelles Based on Poly(ethylene glycol)-b-poly(N-2-hydroxypropyl methacrylamide)−Lipoic Acid Conjugates for Triggered Intracellular Anticancer Drug Release. Biomacromolecules 2012;13: 2429-2438.

9. Lei L, Cheng L, Hou J, Guo S, Zhu C, Shi Y, et al. Prevention of Schistosoma japonicum infection in mice with long-acting praziquantel implants. Experimental Parasitology 2012;131:442-447.

10. Cheng L, Lei L, Guo S, Zhu C, Rong H, Guo D, et al. Schistosoma japonicum: Treatment of different developmental stages in mice with long-acting praziquantel implants. Experimental Parasitology 2011;129(3):254-259..

11. Hou J, Li C, Cheng L, Guo S, Zhang Y, Tang T. Study on hydrophilic 5-fluorouracil release from hydrophobic poly(epsilon-caprolactone) cylindrical implants. Drug Development and Industrial Pharmacy 2011;37(9):1068-1075.

12. Cheng L, Lei L, Guo S. In vitro and in vivo evaluation of praziquantel loaded implants based on PEG/PCL blends. International Journal of Pharmaceutics 2010;387:129-138.

13. Li C, Cheng L (co-first author), Guo S, Wu W. Effects of implant diameter, drug loading and end-capping on praziquantel release from PCL implants. International Journal of Pharmaceutics 2010;386:23-29.

14. Cheng L, Guo S, Wu W. Characterization and in vitro release of praziquantel from poly(ε-caprolactone) implants. International Journal of Pharmaceutics 2009;377:112-119.

15. Yang H, Cheng L, Guo S. Study on acicular poly(ε-caprolactone) implants containing 5-fluorouracil. Chinese Pharmaceutical Journal 2009;44:602-606.

16. Wang S, Guo S, Cheng L. Disodium norcantharidate loaded poly(ε-caprolactone) microspheres: I. Preparation and evaluation. International Journal of Pharmaceutics 2008;350(1-2):130-137.

Back